共 50 条
- [31] Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivativesRSC MEDICINAL CHEMISTRY, 2021, 12 (03): : 430 - 438Sanachai, KamonpanAiebchun, ThitinanMahalapbutr, PanupongSeetaha, SupaphornTabtimmai, LueachaMaitarad, PhornphimonXenikakis, IakovosGeronikaki, AthinaChoowongkomon, KiattaweeRungrotmongkol, Thanyada
- [32] Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3Molecular Diversity, 2024, 28 : 497 - 507Hemantkumar DeokarMrunalini DeokarJohn K. Buolamwini
- [33] Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3MOLECULAR DIVERSITY, 2024, 28 (02) : 497 - 507Deokar, HemantkumarDeokar, MrunaliniBuolamwini, John K. K.
- [34] The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)BLOOD, 2022, 140 : 6722 - 6723Rai, ShivamStetka, JanUsart, MarcHao-Shen, HuiPark, YoungHouston, RemieMartinez Benitez, Anthony R.Wereski, MatthewGuzzardi, EmilyPersaud, SonaliRamzan, HaileyFutran, AlanXu, CharleyGreenwood, JeremyMondal, SayanMasse, CraigLevine, Ross L.Skoda, Radek C.Dunbar, Andrew
- [35] Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 InhibitorsJOURNAL OF CHEMICAL INFORMATION AND MODELING, 2019, 59 (12) : 5002 - 5012Yang, MinjianTao, BingzhongChen, ChengjuanJia, WenqiangSun, ShaoleiZhang, TiantaiWang, Xiaojian
- [36] CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLeukemia, 2009, 23 : 1441 - 1445A PardananiT LashoG SmithC J BurnsE FantinoA Tefferi
- [37] CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLEUKEMIA, 2009, 23 (08) : 1441 - 1445Pardanani, A.Lasho, T.Smith, G.Burns, C. J.Fantino, E.Tefferi, A.
- [38] Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (12) : 1522 - 1531Zak, MarkHanan, Emily J.Lupardus, PatrickBrown, David G.Robinson, ColinSiu, MichaelLyssikatos, Joseph P.Romero, F. AnthonyZhao, GuilingKellar, TerryMendonca, RohanRay, Nicholas C.Goodacre, Simon C.Crackett, Peter H.McLean, NevilleHurley, Christopher A.Yuen, Po-waiCheng, Yun-XingLiu, XiongcaiLiimatta, MaryaKohli, Pawan BirNonomiya, JimSalmon, GaryBuckley, GerryLloyd, JuliaGibbons, PaulGhilardi, NicoKenny, Jane R.Johnson, Adam
- [39] JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor α and βc subunit, respectively, and are activated upon IL-5 stimulationBLOOD, 1998, 91 (07) : 2264 - 2271Ogata, NKouro, TYamada, AKoike, MHanai, NIshikawa, TTakatsu, K
- [40] Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227Yu, JiangLuo, LinglingHu, TongCui, YatingSun, XiaoGou, WenfengHou, WenbinLi, YiliangSun, Tiemin